Kalaris Therapeutics Inc Stock Price, News & Analysis

Kalaris (Nasdaq: KLRS) reported Q3 2025 results and business updates on Nov 12, 2025. The company had $77.0M in cash, cash equivalents and short-term investments as of Sep 30, 2025, which it expects will fund operations into 2027. Clinical progress includes a Phase 1a single ascending dose trial with initial data expected by year-end 2025 and a newly initiated Phase 1b/2 multiple ascending dose trial enrolling up to 80 nAMD patients with initial data expected in 2H 2026. Kalaris entered a formal CDMO agreement with KBI Biopharma, hired a new CFO, and opened headquarters in Berkeley Heights, NJ. Q3 net loss was $11.9M; shares outstanding were 18,702,418.

Kalaris (NASDAQ:KLRS) appointed Matthew Gall, MBA as Chief Financial Officer effective Nov 3, 2025.

The hire strengthens Kalaris’ leadership as the company enrolls its Phase 1b/2 study in treatment‑naïve nAMD patients. Gall previously served as CFO of iTeos Therapeutics and held finance and business development roles at Sarepta, Celgene, and Gilead. He holds a BS in Business Administration from Bowling Green State University and an MBA from The University of Chicago.

The company described the appointment as supporting capital strategy, business development and scaling during clinical advancement.

Kalaris (Nasdaq: KLRS) announced that company management will present at the Stifel 2025 Annual Healthcare Conference on Thursday, November 13, 2025 from 3:20–3:50pm ET at the Lotte New York Palace Hotel in New York, NY.

Speakers listed are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO. Management will be available for one-on-one meetings during the conference; interested parties should contact their conference representative to arrange a meeting.

Kalaris Therapeutics (NASDAQ:KLRS) has begun enrolling patients in a Phase 1b/2 multiple ascending dose (MAD) study for TH103, targeting neovascular age-related macular degeneration (nAMD). The study will evaluate multiple dose levels in up to 80 nAMD patients, who will receive 4 monthly intravitreal injections.

The Phase 1b/2 study replaces a smaller Part 2 design and will inform dose selection for potential Phase 3 development. Initial data is expected in 2H 2026. Meanwhile, the ongoing Phase 1a single ascending dose study remains on schedule to report data in Q4 2025.

TH103, developed by Lasker Award recipient Dr. Napoleone Ferrara, represents a novel approach to treating exudative and neovascular retinal diseases, building on anti-VEGF therapy research.

Kalaris Therapeutics (NASDAQ:KLRS) has initiated enrollment for a Phase 1b/2 multiple ascending dose (MAD) study of TH103 in patients with neovascular age-related macular degeneration (nAMD). The study will evaluate up to 80 nAMD patients who will receive up to 4 monthly intravitreal injections of TH103.

The company expects to report initial data from the ongoing Phase 1a single ascending dose study in Q4 2025, with Phase 1b/2 data anticipated in 2H 2026. TH103, developed by Lasker Award recipient Dr. Napoleone Ferrara, represents a novel approach to treating exudative and neovascular retinal diseases, building on anti-VEGF therapy research.

Kalaris Therapeutics (NASDAQ:KLRS), a clinical-stage biopharmaceutical company focusing on retinal diseases, reported Q2 2025 financial results and provided business updates. The company continues enrolling patients in its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular Age-related Macular Degeneration (nAMD), with initial clinical data expected in Q4 2025.

Financial highlights include cash position of $88.4 million as of June 30, 2025, expected to fund operations into Q4 2026. Q2 2025 resulted in a net loss of $11.4 million ($0.61 per share). The company strengthened its leadership team with the addition of Kristine Curtiss as SVP of Clinical, bringing 25 years of ophthalmology expertise.

Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The company's management team, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will deliver a presentation in a fireside Q&A format on Thursday, June 5th, 2025, at 3:00 PM ET. The presentation will be accessible via webcast, with a replay available afterward on Kalaris' Investor Relations webpage. The company aims to showcase its developments in retinal disease therapeutics to the investment community.

Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will engage in a Fireside Chat on Tuesday, May 27th, 2025, at 8:00 AM ET. A replay of the event will be available on the company's Investor Relations webpage.

Kalaris Therapeutics (NASDAQ: KLRS) reported its Q1 2025 financial results and provided business updates. The company is advancing its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular age-related macular degeneration (nAMD). Initial clinical data is expected in Q4 2025.

Financial highlights include cash and cash equivalents of $101.0 million as of March 31, 2025, up from $1.6 million in December 2024, primarily due to the AlloVir merger. The company reported a net loss of $10.2 million ($2.52 per share) compared to $3.4 million ($2.60 per share) in Q1 2024. R&D expenses increased to $6.0 million from $2.0 million, while G&A expenses rose to $4.3 million from $0.6 million year-over-year.